Navigation Links
China Yingxia International Announces Soybean Milk Production Lines Acquisition
Date:3/28/2008

NEW YORK, March 28 /Xinhua-PRNewswire-FirstCall/ -- China Yingxia International, Inc. (OTC Bulletin Board: CYXI), (the "Company") a leading provider in the nutraceutical industry engaged in the development, manufacture and distribution of organic nutritional food products, supplements, and personal care products in China, today announced that it is in the final stages of the acquisition of six soybean milk production lines from King International Food Corporation Limited ("King"), a Sino-Australian joint venture.

The Company has spent over $4 million dollars to acquire production equipment, technical know-how, and marketing resources from King. The Company is now in the process of engaging a third party to provide an asset evaluation report to formally complete the purchase of the production lines. The Company expects the transaction to be completed before the end of the second quarter of 2008.

"We expect to begin production by the end of the second quarter after the acquisition formally closes," stated Ms. Yingxia Jiao, the Company's chairwoman. "This marks our first step toward becoming a major player in the soy milk business in China. We have other exciting projects in the pipeline for this year and I hope you can all join me for our fourth quarter and 2007 full year conference call next Monday."

About China Yingxia International, Inc.

China Yingxia International, Inc., through its 100%-owned subsidiary, Harbin Yingxia Industrial Group Co., Ltd. ('Yingxia'), is primarily engaged in the development, production and sales of health food products in China. Yingxia is located in the Province of Heilongjiang in mainland China. Yingxia's products include soybean-based foods and drinks, longgu golden millet enriched products, cactus-based herbal supplements, personal care products, Nestle products, and organic rice products.

Safe Harbor Statement

The statements contained herein that are not historical facts are 'forward-looking statements' within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by, among other things, the use of forward-looking terminology such as 'believes,' 'expects,' 'may,' 'will,' 'should,' or 'anticipates' or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. In particular, our statements regarding the potential growth of the markets are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including but not limited to, general economic conditions and regulatory developments, not within our control. The factors discussed herein and expressed from time to time in our filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed or implied by such statements. The forward-looking statements are made only as of the date of this filing, and we undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

For more information, please contact:

Peter Zhou

Tel: +1-212-232-0058


'/>"/>
SOURCE China Yingxia International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cells from the Research Institute of the MUHC on the road to China
2. China Medicine Announces Record Fourth Quarter and Fiscal Year 2007 Results
3. China Yingxia International Announces 2007 Fourth Quarter and Full Year Financial Results Conference Call
4. China Medicine Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
5. China RuiTai International Holdings Retains CCG Elite for Investor Relations Services
6. China Medical Technologies Receives CE Mark for Two ECLIA Analyzers and 15 Reagents
7. Sinovac to Present at the Brean Murray, Carret & Co. Fourth Investor Tour of China
8. China Nepstar Chain Drugstore Announces Dividend
9. Alsius Corporation Receives Regulatory Approval in China and Mexico
10. Mirion Technologies to Showcase New Product Offerings for the Nuclear Industry During 10th Annual China International Nuclear Industry Exhibition
11. China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... ... Pastor and Overseer at The House of Yahweh in Abilene, Texas, has published a new ... not. Yisrayl says with so many titles and names for the Creator, it’s hard ... a little Scripture, backed with a lot of research, the truth is undeniable. , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation Limited, a ... its Nova Skin Sciences division, recently announced the launch of Allumière Antiaging Cream, ... power of an anti-aging concentrate. , Anogeissus Leiocarpa Bark Extract and ...
(Date:4/28/2017)... Tenn. (PRWEB) , ... April 28, 2017 , ... ... system, today announced an alliance with B. Braun Medical Inc. , a leader ... role in patient care with as many as 90 percent of hospital patients receiving ...
(Date:4/27/2017)... , ... April 27, 2017 , ... ... natural deodorant. On the heels of Thinksport’s award-winning sunscreen they’ve used the same ... that actually works! , Countless deodorants flood the aisles that contain harmful chemicals ...
(Date:4/27/2017)... ... April 27, 2017 , ... Goodcents Deli Fresh Subs announced ... Lincoln, Neb. area this year. , The first new location will open at ... will open at 84th and Northern Lights Drive this fall. And the third location ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
(Date:4/19/2017)... N.J. , April 19, 2017  Novartis ... by the National Heart, Lung, and Blood Institute ... demonstrating that 58% of patients with treatment-naïve severe ... months when treated with eltrombopag at the initiation ... . The study evaluated three sequential treatment groups, ...
Breaking Medicine Technology: